Potency Is Not One Number — and the Lab Data Shows Exactly How Far It Spreads
Most writing about Amanita muscaria potency stops at "it varies." The published analytical chemistry is more specific than that, and more useful. When Japanese forensic scientists measured ibotenic acid and muscimol in Amanita caps by GC/MS, they found ibotenic acid ranging from under 10 ppm to 2,845 ppm and muscimol from 46 to 1,052 ppm across their A. muscaria samples (Tsujikawa et al., Forensic Science International, 2006). That is a spread of more than two orders of magnitude within a single species. Two caps of identical weight, from the same shipment, can carry wildly different amounts of the compounds that actually do something — which is why weight is a measure of material, not a measure of dose.
Species Is the Largest Single Variable, and It Isn't Always Obvious on the Shelf
The same 2006 analysis measured Amanita pantherina alongside A. muscaria and found a strikingly different chemical profile: pantherina caps carried 1,554–1,880 ppm muscimol against muscaria's 46–1,052 ppm, while its ibotenic acid sat lower at 188–269 ppm. Same genus, same section, visually distinguishable only if you know what you're looking at — and a fundamentally different ratio of the two active compounds. A broader 2023 survey in Toxicon analysed 84 samples across 24 Amanita section Amanita species by UPLC-MS/MS and found that only 10 of the 24 contained ibotenic acid and muscimol at all, with ibotenic acid spanning 0.61 to 32.09 g/kg dry weight (Toxicon, 2023, PMID 37611670). If you cannot name the species with confidence, you cannot reason about potency at all — the range across the genus is roughly fifty-fold. This is the practical case for buying whole, identifiable specimens from a named species rather than ground material: our Amanita pantherina and Grade A Amanita muscaria caps are listed separately precisely because they are not interchangeable.
Cap, Stalk, or Base: Which Tissue You Use Changes the Result
Ibotenic acid and muscimol are not distributed evenly through the fruiting body. Measuring across whole mushrooms, Tsunoda and colleagues found mean concentrations of 519 ppm ibotenic acid and 30 ppm muscimol in the cap, 290 and 20 ppm in the base, and 253 and 17 ppm in the stalk (Tsunoda et al., Food Hygiene and Safety Science, 1993). The 2006 forensic work adds a finer point: within the cap, the compounds tended to concentrate in the flesh rather than the cuticle — the red skin most people treat as the "active" part. So a preparation built from whole mushrooms including stalks is meaningfully weaker per gram than one built from caps alone, and peeling the cuticle does not remove the actives. Neither of those facts is visible on a scale.
Two Things That Commonly Get Blamed for Potency — and Probably Shouldn't
Vendor copy frequently claims that specimens harvested at peak season from a particular region deliver consistent potency. The Tsunoda data does not support the mechanism behind that claim. Growing location had no measurable influence on ibotenic acid or muscimol concentration in their samples, and neither did mushroom size. More striking still: as the fruit body matured to roughly six times its earlier weight, ibotenic acid concentration remained nearly constant — the mushroom got bigger without getting proportionally more or less loaded. A separate finding in the 2023 Toxicon work showed A. subglobosa toxin levels decreasing at the mature stage, so maturity effects are real in some species but clearly not uniform across the genus. The honest reading is that specimen-to-specimen variation dominates, and that region-and-season marketing is a story about sourcing standards and handling, not a verified potency control. That distinction matters, and it is separate from what a grade label does or doesn't certify — a subject we cover in our guide to what "premium" Amanita actually means.
Drying Shifts the Ratio, but Not Predictably Enough to Treat as a Dose Control
Drying and heat drive decarboxylation of ibotenic acid into muscimol, which is why dried material is chemically different from fresh (Tsunoda et al., 1993). What often gets lost is that the conversion is partial and inconsistent. In fresh tissue the ibotenic-acid-to-muscimol ratio runs roughly 9:1 or higher; in dried material ibotenic acid typically still exceeds muscimol, commonly cited around 3:2. The conversion depends on drying time, temperature, and airflow, none of which are standardised across suppliers. So "properly dried" tells you a process was followed, not that a specific ratio was achieved. If you want the underlying chemistry of how each method changes what you end up consuming, our breakdown of tea, tincture, capsule, and parboiling chemistry goes through it method by method.
The Product-Form Problem: Sometimes "Amanita" Isn't Amanita
Everything above assumes the product contains what it claims. In the processed-edible market, that assumption has repeatedly failed. A CDC MMWR field report examined six packages across five brands of mushroom gummies marketed as nootropics and found unlabeled psilocybin or psilocin — Schedule I substances — in four of the six, along with undisclosed caffeine, ephedrine, and mitragynine; ibotenic acid and muscimol themselves could not be confirmed present (CDC MMWR, 2024). Five people, including a child, required emergency evaluation. This is not new: the 2006 Japanese forensic analysis found that the four commercial "Amanita" extract products it tested contained little or no detectable ibotenic acid or muscimol, but did contain tryptamine derivatives, monoamine oxidase inhibitors, and tropane alkaloids. The failure modes are genuinely different by product form. With whole dried caps you have a known species and an unknown potency. With gummies, vapes, and unlabeled extracts you may have an unknown everything — which is why we sell whole dried caps rather than edibles, and why intact, inspectable specimens are the only format where a buyer can independently verify the species at all.
What Regulators Have Actually Said About This
In a scientific memorandum publicised in December 2024, the U.S. FDA concluded that Amanita muscaria, its extracts, and the constituents muscimol, ibotenic acid, and muscarine do not meet the Generally Recognized as Safe standard, are unapproved food additives, and render any conventional food containing them adulterated under the FD&C Act (FDA scientific memorandum, 2024). Enforcement followed, including a September 2025 warning letter to a manufacturer over Amanita-containing products. Two things follow from this. First, no agency is verifying potency or purity on your behalf — the regulatory posture is the opposite of approval. Second, availability is not a safety signal, and the legal picture varies sharply by jurisdiction; our guide to the global legal landscape covers where that currently stands and why it keeps moving.
What Safe Practice Means When the Dose Genuinely Cannot Be Verified
The clinical record makes the stakes concrete. A 2022 case report in Wilderness & Environmental Medicine documented two severe poisonings including a fatality at doses of just four to five dried caps, with onset between 30 minutes and 2 hours (Meisel et al., 2022). A 2025 Lithuanian case series described four hospitalisations from intentional recreational use, one after only three dried mushrooms, which progressed to respiratory failure requiring mechanical ventilation (Acta Medica Lituanica, 2025). Given the analytical spread described above, none of those case doses can be translated into a milligram figure — which is the entire problem. Practically, that means treating every new batch as an unknown quantity regardless of what the previous one felt like, never combining it with alcohol or sedative medication given muscimol's GABA-A activity, storing it well away from children and pets, and understanding that Amanita muscaria is not an evidence-based treatment for anxiety, sleep, or any diagnosed condition — anyone considering it for those reasons should speak to a healthcare professional first. Our fly agaric facts, risks and safe-use guide and our practical guide to mindful use go deeper on both.
Frequently Asked Questions
How much does Amanita muscaria potency actually vary between mushrooms?
Forensic analysis of A. muscaria caps measured ibotenic acid from under 10 ppm to 2,845 ppm and muscimol from 46 to 1,052 ppm — more than a hundredfold spread within one species (Tsujikawa et al., 2006). Weight is not a proxy for potency.
Is Amanita pantherina stronger than Amanita muscaria?
They are chemically different rather than simply stronger or weaker. The same 2006 analysis found pantherina caps higher in muscimol (1,554–1,880 ppm) but lower in ibotenic acid (188–269 ppm) than muscaria, meaning a different balance of the two compounds rather than a scaled-up version of the same thing.
Which part of the mushroom is most concentrated?
The cap, followed by the base, with the stalk lowest — mean values of 519, 290, and 253 ppm ibotenic acid respectively (Tsunoda et al., 1993). Within the cap, concentrations tend to be higher in the flesh than in the red cuticle.
Does the region or season a mushroom was harvested in determine its potency?
Not according to the available measurements. Tsunoda and colleagues found growing location and mushroom size had no measurable influence on ibotenic acid or muscimol concentration, and concentration stayed roughly constant as the fruit body grew sixfold. Region and season are sourcing and handling claims, not potency guarantees.
Does drying make Amanita muscaria stronger?
Drying converts part of the ibotenic acid into muscimol, changing the compound ratio rather than reliably increasing total potency. The conversion is incomplete and varies with drying time, temperature, and airflow, so it cannot be treated as a standardisation step.
Are Amanita gummies and edibles more consistent than dried caps?
Testing suggests the opposite risk profile. A CDC MMWR investigation found unlabeled psilocybin or psilocin in four of six mushroom gummy packages tested, alongside undisclosed caffeine, ephedrine, and mitragynine, with the labeled Amanita compounds unconfirmed. Whole dried caps carry unknown potency; unverified edibles can carry unknown contents entirely.
Is Amanita muscaria approved or regulated for food use?
No. The FDA determined in a 2024 scientific memorandum that A. muscaria, its extracts, muscimol, ibotenic acid, and muscarine do not meet the GRAS standard and are unapproved food additives, making conventional foods containing them adulterated under the FD&C Act. No agency verifies potency or purity for consumers.
Bottom Line
Potency in Amanita muscaria is driven by things a buyer can partly control — species identity, which tissue is used, and whether the product is an inspectable whole specimen or an opaque processed edible — and by one thing nobody can control, which is the enormous natural variation between individual mushrooms. The measured ranges are wide enough that no gram figure carries reliable meaning, and no grading label, harvest region, or drying claim closes that gap. The defensible position is to buy identifiable material from a named species, treat every batch as chemically unknown, and never assume that what worked before will behave the same way again.
Always use Amanita muscaria responsibly and research local regulations before purchase. This article is informational and is not medical advice.
About the author: Viktor writes about mushroom chemistry, sourcing, and safety for Amanita Store, with a focus on what published analytical data actually supports.